Commitment
Andarix Pharmaceuticals is developing and commercializing novel cancer therapies that are targeted to the patients most likely to respond. Tozaride, our lead product entering Phase 2 clinical trials, targets specific cancers at the molecular level, and its companion diagnostic identifies the patients with the corresponding molecular signature who are the best candidates for therapy.

News & Events
Andarix Pharmaceuticals to Present Lung Cancer Clinical Trial Results at the Society of Nuclear Medicine Meeting.
Targeted therapy for lung cancer is based on personalized medicine approach SOMERVILLE, MA — October 26, 2018— ANDARIX Pharmaceuticals, a leader in the discovery and development of targeted peptide therapy for cancer announced today that it will present the results of its latest clinical trial in lung cancer patients. The trial focused on the administration…
Read MoreAndarix Pharmaceuticals to present at the CBI Basket and Umbrella Trials for Oncology Conference
Targeted therapy for lung cancer is based on personalized medicine approach SOMERVILLE, MA — October 18, 2018— ANDARIX Pharmaceuticals, a leader in the discovery and development of targeted peptide therapy for cancer announced today that it will present strategies for broad-based or basket clinical trials in lung cancer. The presentation will take place at the…
Read MoreAndarix Pharmaceuticals Selected to Present at the 6th JCA-AACR Special Joint Conference on Lung Cancer
The Andarix drug addresses the growing Lung Cancer problem in Asia SOMERVILLE, Mass.— July 10, 2018 — Andarix Pharmaceuticals, a clinical stage company, developing a targeted peptide therapy for small cell lung cancer has been selected to present a poster at the 6th JCA-AACR Special Joint Conference on lung cancer from July 10-12 in Kyoto,…
Read More